Addus HomeCare (ADUS)
Market Price (12/20/2025): $112.11 | Market Cap: $2.0 BilSector: Health Care | Industry: Health Care Services
Addus HomeCare (ADUS)
Market Price (12/20/2025): $112.11Market Cap: $2.0 BilSector: Health CareIndustry: Health Care Services
Investment Highlights
Why It Matters
Which of these 2 stories sounds closer for this stock?
1. Generates cash flow
The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.
2. Riding a trend
Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow
| Low stock price volatilityVol 12M is 31% | Weak multi-year price returns2Y Excs Rtn is -23%, 3Y Excs Rtn is -65% | Key risksADUS key risks include [1] the potential failure to successfully integrate acquisitions and achieve anticipated synergies from its M&A-focused growth strategy. |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Remote Patient Monitoring, Show more. |
| Low stock price volatilityVol 12M is 31% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Remote Patient Monitoring, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -23%, 3Y Excs Rtn is -65% |
| Key risksADUS key risks include [1] the potential failure to successfully integrate acquisitions and achieve anticipated synergies from its M&A-focused growth strategy. |
Valuation, Metrics & Events
ADUS Stock
Why The Stock Moved
Qualitative Assessment
AI Generated Analysis | Feedback
The stock of Addus HomeCare (ADUS) experienced a period of decline around early December 2025, with notable drops occurring between December 2nd and December 4th. Specifically, the stock closed at $120.07 on December 2, 2025, and fell to $117.89 by December 3, 2025, representing an approximate 1.8% decrease. This was followed by another drop to $114.16 on December 4, 2025, a further decline of about 3.1%. While the available information does not explicitly detail a single catalyst causing an exact 2% decline, the following points highlight potential factors contributing to the stock's negative movement during this approximate period, considering the general market sentiment and company-specific news: 1. 1. Broader Market or Sector-Specific Headwinds: The stock's movement in early December 2025 could be influenced by general market trends or specific challenges within the healthcare or home care sector. 2. 2. Analyst Sentiment and Price Target Revisions: Although the consensus analyst rating for ADUS was "Moderate Buy" with an average price target of $137.11 as of late 2025, any subtle shifts in analyst sentiment or minor price target adjustments around this period could have contributed to a slight downturn. 3.
Show moreStock Movement Drivers
Return vs. Risk
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ADUS Return | 20% | -20% | 6% | -7% | 35% | -11% | 15% |
| Peers Return | � | � | � | � | � | 50% | � |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 16% | 112% |
Monthly Win Rates [3] | |||||||
| ADUS Win Rate | 58% | 33% | 50% | 50% | 67% | 58% | |
| Peers Win Rate | � | � | � | � | 56% | 58% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| ADUS Max Drawdown | -50% | -37% | -25% | -21% | -7% | -28% | |
| Peers Max Drawdown | � | � | � | � | � | -15% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: EHAB, ENSG, AVAH, CHE, BTSG. See ADUS Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/19/2025 (YTD)
How Low Can It Go
| Event | ADUS | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -44.9% | -25.4% |
| % Gain to Breakeven | 81.5% | 34.1% |
| Time to Breakeven | 902 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -53.4% | -33.9% |
| % Gain to Breakeven | 114.5% | 51.3% |
| Time to Breakeven | 219 days | 148 days |
| 2018 Correction | ||
| % Loss | -23.1% | -19.8% |
| % Gain to Breakeven | 30.0% | 24.7% |
| Time to Breakeven | 154 days | 120 days |
Compare to CVS, CI, LH, DGX, DVA
In The Past
Addus HomeCare's stock fell -44.9% during the 2022 Inflation Shock from a high on 1/22/2021. A -44.9% loss requires a 81.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Latest Trefis Analyses
| Title | Topic | Date | |
|---|---|---|---|
| DASHBOARDS | |||
| Addus HomeCare Earnings Notes | |||
| How Low Can Addus HomeCare Stock Really Go? | Return | ||
| ADUS Dip Buy Analysis | |||
| Addus HomeCare (ADUS) Operating Cash Flow Comparison | Financials | ||
| Addus HomeCare (ADUS) Net Income Comparison | Financials | ||
| Addus HomeCare (ADUS) Operating Income Comparison | Financials | ||
| Addus HomeCare (ADUS) Revenue Comparison | Financials | ||
| Addus HomeCare vs. S&P500 Correlation | Correlation | ||
| Addus HomeCare Price Volatility | Volatility | ||
| Addus HomeCare (ADUS) Stock Has 54% Chance Of Rise In The Next One Month | |||
| ARTICLES | |||
| Better Bet Than RadNet Stock: Pay Less To Get More From ADUS | August 26th, 2025 | ||
| Better Bet Than Premier Stock: Pay Less To Get More From ADUS, CHE | August 16th, 2025 |
Trade Ideas
Select past ideas related to ADUS. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 17.4% | 17.4% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -6.7% | -6.7% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 10.9% | 10.9% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.7% | 2.7% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 11.4% | 11.4% | -5.1% |
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 17.4% | 17.4% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -6.7% | -6.7% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 10.9% | 10.9% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.7% | 2.7% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 11.4% | 11.4% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Addus HomeCare
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 75.16 |
| Mkt Cap | 4.2 |
| Rev LTM | 2,411 |
| Op Inc LTM | 288 |
| FCF LTM | 89 |
| FCF 3Y Avg | 81 |
| CFO LTM | 226 |
| CFO 3Y Avg | 124 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 16.5% |
| Rev Chg 3Y Avg | 11.4% |
| Rev Chg Q | 21.0% |
| QoQ Delta Rev Chg LTM | 4.9% |
| Op Mgn LTM | 8.7% |
| Op Mgn 3Y Avg | 7.5% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 6.8% |
| CFO/Rev 3Y Avg | 7.3% |
| FCF/Rev LTM | 4.6% |
| FCF/Rev 3Y Avg | 4.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 4.2 |
| P/S | 1.2 |
| P/EBIT | 17.3 |
| P/E | 24.5 |
| P/CFO | 20.5 |
| Total Yield | 3.6% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 4.1% |
| D/E | 0.3 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 5.5% |
| 3M Rtn | 11.3% |
| 6M Rtn | 10.7% |
| 12M Rtn | 29.3% |
| 3Y Rtn | 9.7% |
| 1M Excs Rtn | 2.6% |
| 3M Excs Rtn | 6.4% |
| 6M Excs Rtn | -2.3% |
| 12M Excs Rtn | 9.6% |
| 3Y Excs Rtn | -64.8% |
Comparison Analyses
Segment Financials
Revenue by Segment
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Personal Care | 795 | 707 | 686 | 647 | 581 |
| Hospice | 207 | 202 | 152 | 101 | 54 |
| Home Health | 57 | 43 | 26 | 16 | 14 |
| Total | 1,059 | 951 | 864 | 765 | 649 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Personal Care | 158 | 125 | 122 | 107 | 91 |
| Hospice | 45 | 51 | 42 | 29 | 14 |
| Home Health | 7 | 3 | 3 | 1 | 1 |
| Depreciation and amortization | -14 | -14 | -14 | -12 | -11 |
| Other general and administrative expenses | -104 | -96 | -88 | -80 | -61 |
| Total | 91 | 69 | 66 | 45 | 35 |
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/3/2025 | -5.7% | -5.2% | -4.1% |
| 8/4/2025 | 9.0% | 4.7% | 5.7% |
| 5/5/2025 | 4.1% | 5.9% | 7.3% |
| 2/24/2025 | -10.4% | -12.7% | -12.7% |
| 11/4/2024 | -3.7% | -0.8% | -4.2% |
| 8/5/2024 | 5.8% | 6.6% | 10.9% |
| 5/6/2024 | 6.8% | 13.0% | 17.2% |
| 2/26/2024 | 5.5% | 9.6% | 17.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 13 | 12 | 10 |
| # Negative | 7 | 8 | 10 |
| Median Positive | 5.8% | 6.8% | 7.5% |
| Median Negative | -5.2% | -5.3% | -6.0% |
| Max Positive | 12.9% | 13.0% | 17.4% |
| Max Negative | -14.8% | -17.9% | -25.4% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11042025 | 10-Q 9/30/2025 |
| 6302025 | 8052025 | 10-Q 6/30/2025 |
| 3312025 | 5062025 | 10-Q 3/31/2025 |
| 12312024 | 2252025 | 10-K 12/31/2024 |
| 9302024 | 11052024 | 10-Q 9/30/2024 |
| 6302024 | 8062024 | 10-Q 6/30/2024 |
| 3312024 | 5072024 | 10-Q 3/31/2024 |
| 12312023 | 2272024 | 10-K 12/31/2023 |
| 9302023 | 10312023 | 10-Q 9/30/2023 |
| 6302023 | 8012023 | 10-Q 6/30/2023 |
| 3312023 | 5022023 | 10-Q 3/31/2023 |
| 12312022 | 2282023 | 10-K 12/31/2022 |
| 9302022 | 11012022 | 10-Q 9/30/2022 |
| 6302022 | 8022022 | 10-Q 6/30/2022 |
| 3312022 | 5032022 | 10-Q 3/31/2022 |
| 12312021 | 2252022 | 10-K 12/31/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |